Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
QCOM$160.48-12.71(-7.34%)Qualcomm (QCOM) Tops Q4 Earnings and Revenue Estimates6:16:07 PM ETQCOM$160.48-12.71(-7.34%)Qualcomm Stock Down 8% Post Earnings Beat: The Market Lost Its Mind6:15:22 PM ETINTC$58.22-2.28(-3.77%)Intel: The Foundry Trap Is Getting Worse5:48:47 PM ETCVX$216.30-0.66(-0.30%)Joe Terranova Says “Inflation Lost” on Election Night. What That Means for Energy Stocks5:07:08 PM ETQCOM$160.48-12.71(-7.34%)Qualcomm's stock falls as twin forces pressure sales5:03:00 PM ETORCL$124.20+0.47(+0.38%)Wednesday's Final Takeaways: CVS Splitting in Two, ORCL Scraps Tencent Deal5:00:33 PM ETORCL$124.20+0.47(+0.38%)Stock Market Today, Nov. 4: Oracle Falls on Canceled $7 Billion Tencent Chip-Leasing Deal5:00:02 PM ETSPCX$134.99-0.93(-0.68%)How Much Is SpaceX's AI Business Really Worth? Here's the Math.4:59:00 PM ETAMZN$265.76-0.27(-0.10%)Stock Market Today, Nov. 4: Amazon Jumps 6% From New Perspective on AWS Growth and AI Strategy Following Election Results4:53:28 PM ETMETA$631.85+1.85(+0.29%)Meta isn't naming its AI models after fruit anymore4:53:20 PM ETAAPL$350.16+0.65(+0.19%)Apple (AAPL)) Price Forecast: Record High Follows Dramatic Reversal4:52:47 PM ETQCOM$160.48-12.71(-7.34%)Qualcomm's Phone Chip Sales Drop 26%: Rapid Earnings Reaction4:50:19 PM ETQCOM$160.48-12.71(-7.34%)Why Qualcomm investors aren't celebrating the Q4 earnings beat4:44:20 PM ETHD$354.19-1.25(-0.35%)Here's What Democrats Taking Back the House and Senate Could Mean for Housing Stocks Like Home Depot and Lowe's4:40:29 PM ETQCOM$160.48-12.71(-7.34%)Qualcomm Revenue Falls as Handset Slowdown Offsets Automotive Gains4:34:00 PM ETQCOM$160.48-12.71(-7.34%)Qualcomm Q4 Highlights: Double Beat, Company Looks Ahead to 'Ramp of our Data Center Business'4:26:13 PM ETARM$188.00-3.80(-1.98%)Arm Shares Slip Despite Q2 Double-Beat: Details4:20:16 PM ETARM$188.00-3.80(-1.98%)Arm Holdings Sales Climb 27% on AI Demand4:20:00 PM ETWMT$129.02-0.15(-0.12%)Walmart (WMT) Stock Is Down 3%. Here's Why I'd Buy in November and Hold for a Decade.4:20:00 PM ETAAPL$350.16+0.65(+0.19%)Apple cements its status as tech's biggest heavyweight with the stock's best day in over a year4:17:00 PM ETAMZN$265.76-0.27(-0.10%)Palmetto Publishing Releases Dr. Nakia Wilson's New Picture Book About a Beloved Uncle With Disabilities4:16:00 PM ETTPL$299.00+11.35(+3.95%)Texas Pacific Land Corporation Announces Third Quarter Results4:15:00 PM ETCOST$1,060.56+14.09(+1.35%)Costco Wholesale Corporation Reports October Sales Results4:15:00 PM ETMETA$631.85+1.85(+0.29%)Meta acquires AI coding startup Conductor4:10:56 PM ET

VRDN · NASDAQ

Viridian Therapeutics, Inc.

$29.50 +4.41 (+17.55%)

Company overview

Viridian Therapeutics, Inc. is a biotechnology company that develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in a Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED), VRDN-002, an IGF-1R antibody in a Phase 1 clinical trial, and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.3B
Employees
143
Headquarters
Waltham, MA
Website
viridiantherapeutics.com
CEO
Stephen F. Mahoney
Listed
June 18, 2014
P/E
-8.48
Dividend yield
0.00%

Company financials

Revenue
$70.9M
Gross profit
$70.5M
Operating income
-$386M
EBITDA
-$364M
Net income
-$361M
EPS
-$3.48
Total assets
$789M
Total debt
$51.2M
Gross margin
99.38%
Net margin
-508.46%
Earnings yield
-11.80%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

12.7216.2219.7323.2326.73
VRDN 1D NASDAQ O25.61H26.21L24.52C25.15-0.15 (-0.59%)Vol4.06M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
VRDNViridian Therapeutics, Inc. Stock news What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call MarketBeat
VRDNViridian Therapeutics, Inc. Stock news Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript Seeking Alpha
VRDNViridian Therapeutics, Inc. Stock news Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates Zacks Investment Research
VRDNViridian Therapeutics, Inc. Stock news Viridian posts first Lumvoa revenue but net loss widens Reuters
VRDNViridian Therapeutics, Inc. Press release Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress Business Wire
VRDNViridian Therapeutics, Inc. Press release Viridian Metals Announces Private Placement of up to $5.0 Million of Flow-Through and Hard Dollar Units ACCESS Newswire
VRDNViridian Therapeutics, Inc. Press release Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken Main GlobeNewswire
VRDNViridian Therapeutics, Inc. Press release Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 Business Wire
VRDNViridian Therapeutics, Inc. Stock news Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Defense World
VRDNViridian Therapeutics, Inc. Stock news Viridian Therapeutics: Two Products, One Commercial Buildout Seeking Alpha
VRDNViridian Therapeutics, Inc. Stock news Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main GlobeNewswire
VRDNViridian Therapeutics, Inc. Stock news Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference Business Wire
VRDNViridian Therapeutics, Inc. Stock news Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN Defense World
VRDNViridian Therapeutics, Inc. Press release Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending GlobeNewswire
VRDNViridian Therapeutics, Inc. Press release Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results Business Wire
VRDNViridian Therapeutics, Inc. Press release Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease Business Wire
VRDNViridian Therapeutics, Inc. Press release Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program GlobeNewswire
VRDNViridian Therapeutics, Inc. Stock news Viridian Therapeutics to Participate in Upcoming June Investor Conferences GuruFocus
VRDNViridian Therapeutics, Inc. Press release Viridian Therapeutics to Participate in Upcoming June Investor Conferences Business Wire
VRDNViridian Therapeutics, Inc. Press release Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project GlobeNewswire
See more
FAQ

Questions about Viridian Therapeutics, Inc.

What does Viridian Therapeutics, Inc. do?
Viridian Therapeutics, Inc. is a biotechnology company that develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in a Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED), VRDN-002, an IGF-1R antibody in a Phase 1 clinical trial, and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
What is VRDN's market cap?
Viridian Therapeutics, Inc. (VRDN) is a listed stock with a live quote. The latest market cap on this page is $3.3B.
Where is Viridian Therapeutics, Inc. headquartered?
Viridian Therapeutics, Inc. is headquartered in Waltham, MA.
How do I get VRDN news from the API?
Call GET /v1/news?tickers=VRDN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does VRDN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VRDN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the VRDN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs